GEN-MKT-18-7897-A
Sep 13, 2017 | Blogs, Life Science Research, Metabolomics | 0 comments
Why is metabolomics important?Metabolomics is the large-scale study of metabolites in biofluids, tissue extracts, or organisms. Metabolites are small (<1000 Da), biologically active molecules such as glucose, cholesterol, creatinine, hormones, lipids, and more.
Metabolomics provides valuable insight into the underlying processes of cells, diseases and, in turn, human health. Metabolites are the ultimate effectors of the cellular machinery, and represent the penultimate step in the progression from the genome, to proteome, to metabolome, to the phenotype.
By studying the metabolome, researchers can measure the dynamics of the cell response to internal or external perturbations, to build a better understanding of the underlying biology from the cell level to the organism level across all species. Such information supports the identification of biomarkers and biological pathways that are active or dormant during states of disease or health.
Why do we need precision medicine?Currently, patients are treated universally according to their disease diagnosis. However, many widely used drugs are ineffective for at least half of patients with diseases such as arthritis, diabetes, asthma, and depression. With the help of biomarkers and companion diagnostics (diagnostic tests used as a companion to a therapeutic drug to determine its applicability to a specific patient), researchers can stratify patients into subsets according to their disease progression and other key factors. This allows better prediction of disease outcomes so that more appropriate treatment regimes can be developed for the different sub groups. In turn, stratified medicine can give rise to precision medicine, where treatment is tailored for each patient according to their medical history, results from other tests, their response to medication and other clinical features.
How can metabolomics enable precision medicine?Collecting comprehensive metabolomics data depends on the simultaneous identification and quantification of hundreds of compounds in every sample. This requires robust, powerful and high-throughput mass spectrometry technologies with a very wide dynamic range to accommodate the diverse set of metabolic components present in a typical sample. Mass spectrometry has been heavily employed in this area due to the sensitivity delivered against other available technologies. With the growing interest in precision medicine, biomedical researchers are becoming increasingly dependent on fast, robust and accurate mass spectrometry-based technologies for comprehensive data collection on an industrialized scale. Users will demand ever-high throughput and accuracy for the rapid and reliable identification and quantification of every compound in thousands of samples.
SolutionsSCIEX offers several market-leading mass spectrometry solutions for metabolomics researchers who are conducting targeted screening of known compounds or carrying out discovery research to globally study the metabolome.
For metabolomics researchers performing longitudinal studies of large cohorts, SWATH Acquisition offers the robust workflow required to accurately identify and quantify nearly every detectable relevant metabolite in the sample. SWATH allows data to enter a permanent digital archive that can be re-interrogated at any time in the future.
Recent advances in mass spec for metabolomics and precision medicine
Future DirectionsThere is increasing interest within the scientific community in applying multi-omics approaches, where data from genomic, metabolomic, phenotypic and other studies are brought together to better inform stratified medicine approaches, and ultimately enable precision medicine.
Want to learn more about metabolomics and precision medicine?
It is no secret that (bio)pharmaceutical research and development is complex, both scientific and regulatory processes. Here is an overview of just some of the ways SCIEX is working to support these challenges.
In a recent webinar, available on demand, scientists Luiza Chrojan and Ryan Hylands from Pharmaron, provided insights into the deployment of capillary gel electrophoresis (CGE) within cell and gene therapy. Luiza and Ryan shared purity data on plasmids used for adeno-associated virus (AAV) manufacturing and data on AAV genome integrity, viral protein (VP) purity and VP ratios using the BioPhase 8800 system.
Last year, Technology Networks hosted two webinars that featured groundbreaking research utilizing SWATH DIA (data-independent acquisition) for exposomics and metabolomics. Researchers Dr. Vinicius Verri Hernandes from the University of Vienna and Dr. Cristina Balcells from Imperial College London (ICL) demonstrated how a DIA approach can be successfully implemented in small molecule analysis using the ZenoTOF 7600 system. Their innovative approaches highlight the potential of SWATH DIA to enhance the detection and analysis of chemical exposures and metabolites, paving the way for new insights into environmental health and disease mechanisms.
Posted by
You must be logged in to post a comment.
Share this post with your network